Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, custirsen, docetaxel, OGX-011, pain, SATURN, survival, synergy | Leave a Comment »
The GETUG 15 trial is a primarily French, multi-center, randomized, controlled, Phase III clinical trial designed to evaluate the relative benefits of chemohormonal vs, hormonal therapy for the treatment of metastatic, hormone-naïve prostate cancer in men with a rising PSA.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, chemohormonal therapy, docetaxel | 2 Comments »
Long-term follow-up data have just been published from two studies designed to provide preliminary information on the potential use of very aggressive forms of treatment in men with high-risk categories of prostate cancer.
Filed under: Management, Treatment | Tagged: aggressive, androgen deprivation, docetaxel, hormone, paclitaxel, radiation, taxane, therapy | 7 Comments »
Several years ago, Bolla et al. planned and carried out the major European trial showing that external beam radiation therapy with 3 years of androgen deprivation therapy (ADT, using goserelin acetate) extended the prostate cancer-specific and the overall survival of patients with high-risk localized prostate cancer as compared to radiation alone.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, ADT, androgen deprivation therapy, chemohormonal, docetaxel, radiation | 2 Comments »
Docetaxel + prednisone is the current standard treatment for men with castration-resistant prostate cancer (CRPC). However, the survival benefit of this form of treatment is small compared to older forms of therapy.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, combination, CRPC, docetaxel, ketoconazole | Leave a Comment »
In March this year it was announced that the combination of bevacizumab (Avastin) with docetaxel and prednisone had no benficial impact (in a large Phase III trial) on the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. There are, naturally, hopes that the outcome might be different if one adds [...]
Filed under: Drugs in development, Management, Treatment | Tagged: bevacizumab, chemotherapy, docetaxel, hornone-refractory, HRPC, thalidomide | Leave a Comment »
Results of a study (the GETUG 12 trial) presented today at the ASCO 2010 Genitourinary Cancer Symposium in San Francisco suggest that the addition of docetaxel-based chemotherapy to androgen deprivation and radiation therapy may impact biochemical recurrence of prostate cancer in high risk patients with localized disease — but it will take a while before [...]
Filed under: Uncategorized | Tagged: "high risk", docetaxel, localized disease | 1 Comment »
According to a media release from Sanofi-Aventis early this morning, the second-generation taxane cabazitaxel, when given in combination with prednisone, is capable of extending median survival by 2.4 months compared to mitoxantrone + prednisone in prostate cancer patients who are refractory to docetaxel (Taxotere) chemotherapy.
Filed under: Drugs in development | Tagged: cabazitaxel, CRPC, docetaxel, mitoxantrone | 3 Comments »
In today’s (slightly belated) news reports, we comment on studies dealing with: A possible association between hypertension and later diagnosis of prostate cancer Appropriate selection of high-risk patients for RALP Optimization of the appropriate use of docetaxel + prednisone in treatment of CRPC
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CRPC, docetaxel, high-risk patients, hypertension, prednisone, RALP, risk, robot-assisted laparoscopic prostatectomy | Leave a Comment »
A new paper by Armstrong et al. has analyzed data from the original TAX327 clinical trial in an attempt to define specific patient “risk groups” based on the participants in that trial and how they responded to docetaxel-based chemotherapy.
Filed under: Management, Treatment | Tagged: chemotherapy, docetaxel, outcomes, reponse, risk groups | Leave a Comment »
We have no idea, prior to treatment, whether a specific individual with hormone-refractory prostate cancer (HRPC) will respond to chemotherapy with docetaxel (Taxotere) — the only form of chemotherapy proven to extend survival of prostate cancer patients in randomized, Phase III clinical trials. However, we do now have some data suggesting that we may be [...]
Filed under: Management, Treatment | Tagged: docetaxel, prognosis, PSA "half-life", survival | 5 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site